Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network

Antimicrobial Agents and Chemotherapy
Yawei ZhangHui Wang

Abstract

Carbapenem-resistant Enterobacteriaceae (CRE) infection is highly endemic in China, but estimates of the infection burden are lacking. We established the incidence of CRE infection from a multicenter study that covered 25 tertiary hospitals in 14 provinces. CRE cases defined as carbapenem-nonsusceptible Citrobacter freundii, Escherichia coli, Enterobacter cloacae, or Klebsiella pneumoniae infections during January to December 2015 were collected and reviewed from medical records. Antimicrobial susceptibility testing and carbapenemase gene identification were performed. Among 664 CRE cases, most were caused by K. pneumoniae (73.9%), followed by E. coli (16.6%) and E. cloacae (7.1%). The overall CRE infection incidence per 10,000 discharges was 4.0 and differed significantly by region, with the highest in Jiangsu (14.97) and the lowest in Qinghai (0.34). Underlying comorbidities were found in 83.8% of patients; the median patient age was 62 years (range, 45 to 74 years), and 450 (67.8%) patients were male. Lower respiratory tract infections (65.4%) were the most common, followed by urinary tract infection (16.6%), intra-abdominal infection (7.7%), and bacteremia (7.7%). The overall hospital mortality rate was 33.5%. All isolates ...Continue Reading

References

Dec 6, 2006·Antimicrobial Agents and Chemotherapy·Zeqing WeiLan-Juan Li
Jun 20, 2008·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Y H XiaoMOH National Antimicrobial Resistance Investigation Net
Dec 7, 2010·The Journal of Antimicrobial Chemotherapy·Yan QiYunsong Yu
Apr 22, 2011·The Journal of Antimicrobial Chemotherapy·Nimish PatelThomas P Lodise
Jun 10, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Neil GuptaAlexander J Kallen
Oct 18, 2011·Emerging Infectious Diseases·Patrice NordmannLaurent Poirel
Apr 18, 2012·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Rafael CantónEuropean Network on Carbapenemases
Jul 4, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Mario TumbarelloMatteo Bassetti
Nov 10, 2013·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Xiaojuan WangHui Wang
Mar 19, 2014·Antimicrobial Agents and Chemotherapy·Zubair A QureshiRyan K Shields
Jun 25, 2014·Emerging Infectious Diseases·Matthew E FalagasKonstantinos Z Vardakas
Apr 23, 2015·The Journal of Antimicrobial Chemotherapy·Mario TumbarelloISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva)
Oct 6, 2015·JAMA : the Journal of the American Medical Association·Alice Y GuhAlexander J Kallen
Dec 15, 2015·The Journal of Antimicrobial Chemotherapy·Yedidah Fraenkel-WandelMarc V Assous
Feb 6, 2016·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A XuC Zhuo
Feb 7, 2016·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·C HauckAntibacterial Resistance Leadership Group
Mar 24, 2016·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·F-P HuW Huang
Jul 13, 2016·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Q WangHui Wang
Nov 22, 2016·The Lancet Infectious Diseases·Hajo GrundmannEuropean Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) Working Group
Dec 26, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Pranita D TammaPatricia J Simner

Citations

Mar 6, 2019·Antimicrobial Agents and Chemotherapy·Jiansheng HuangJiansong Ji
Dec 18, 2019·Antimicrobial Agents and Chemotherapy·Jiansheng HuangZhigang Zhao
Sep 7, 2018·Frontiers in Microbiology·Jiansheng HuangZhigang Zhao
Sep 3, 2020·International Journal of Environmental Research and Public Health·Guoying WangHongju Wang
Nov 4, 2019·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Melanie L YarbroughCarey-Ann D Burnham
Jun 5, 2019·Journal of Laboratory Physicians·Nermin Kamal SaeedMohammed Al-Biltagi
Sep 5, 2019·Frontiers in Microbiology·Xiaoyan CuiHong Du
Apr 17, 2020·Antimicrobial Resistance and Infection Control·Haishaerjiang WushouerXiaodong Guan
Nov 4, 2020·Future Microbiology·Matteo BassettiDaniele R Giacobbe
Feb 4, 2021·The Journal of Antimicrobial Chemotherapy·Ursula TheuretzbacherEvelina Tacconelli
Apr 8, 2021·Expert Opinion on Pharmacotherapy·Joseph P LynchGeorge G Zhanel
Mar 10, 2021·Antimicrobial Agents and Chemotherapy·Lucile PantelMaxime Gualtieri
May 26, 2021·Expert Review of Anti-infective Therapy·Ilias KaraiskosHelen Giamarellou

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.